Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 04, 2023

BUY
$6.36 - $11.47 $311 - $562
49 New
49 $0
Q4 2022

Feb 07, 2023

SELL
$8.32 - $13.21 $2,229 - $3,540
-268 Reduced 27.52%
706 $26,000
Q2 2022

Sep 06, 2022

BUY
$9.99 - $21.35 $9,730 - $20,794
974 New
974 $47,000
Q2 2022

Aug 12, 2022

SELL
$9.99 - $21.35 $9,730 - $20,794
-974 Closed
0 $0
Q1 2022

Sep 06, 2022

BUY
$14.08 - $27.63 $11,503 - $22,573
817 Added 520.38%
974 $18,000
Q4 2021

Jan 12, 2022

SELL
$26.55 - $40.57 $1,380 - $2,109
-52 Reduced 24.88%
157 $5,000
Q3 2021

Oct 06, 2021

BUY
$39.27 - $72.94 $7,854 - $14,588
200 Added 2222.22%
209 $9,000
Q3 2020

Oct 29, 2020

SELL
$28.06 - $37.16 $28 - $37
-1 Reduced 10.0%
9 $0
Q1 2020

May 12, 2020

SELL
$14.88 - $32.78 $2,916 - $6,424
-196 Reduced 95.15%
10 $0
Q4 2019

Jan 17, 2020

SELL
$19.49 - $32.63 $12,785 - $21,405
-656 Reduced 76.1%
206 $6,000
Q3 2019

Nov 07, 2019

SELL
$22.49 - $26.81 $6,049 - $7,211
-269 Reduced 23.78%
862 $19,000
Q1 2019

May 15, 2019

BUY
$19.43 - $26.41 $2,234 - $3,037
115 Added 11.32%
1,131 $28,000
Q4 2018

Jan 23, 2019

BUY
$18.19 - $31.79 $2,983 - $5,213
164 Added 19.25%
1,016 $23,000
Q3 2018

Oct 25, 2018

SELL
$27.65 - $38.39 $718 - $998
-26 Reduced 2.96%
852 $0
Q2 2018

Aug 07, 2018

SELL
$31.4 - $41.01 $4,835 - $6,315
-154 Reduced 14.92%
878 $0
Q1 2018

Jun 03, 2019

BUY
$29.84 - $44.08 $5,371 - $7,934
180 Added 21.13%
1,032 $32,000
Q1 2018

May 09, 2018

SELL
$29.84 - $44.08 $5,371 - $7,934
-180 Reduced 17.44%
852 $0
Q4 2017

Jan 24, 2018

SELL
$21.89 - $31.34 $14,316 - $20,496
-654 Reduced 38.79%
1,032 $0
Q3 2017

Oct 30, 2017

BUY
$15.81 - $24.01 $20,553 - $31,213
1,300 Added 336.79%
1,686 $40,000
Q1 2017

Jun 03, 2019

SELL
N/A
-745 Reduced 65.87%
386 $9,000
Q1 2016

Jun 03, 2019

BUY
N/A
1,131
1,131 $28,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $90M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Ifp Advisors, Inc Portfolio

Follow Ifp Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.